InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
82.97
(
0.14%
)
Bitcoin
67,947.85
(
-2.08%
)
Post# of 251945
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

sks144

Send PM Follow Ignore
Followers 1
Posts 9
Boards Moderated 0
Alias Born 02/15/2023

sks144

Re: iwfal post# 245495

Monday, 02/05/2024 11:45:56 PM

Monday, February 05, 2024 11:45:56 PM

Post# of 251945
Have you seen the final trial design? It’s just one cohort. The 2L setting was eliminated because of uptake of Trodelvy in that setting. The trial is overenrolled and seems adequately powered to me. There wasn’t a material difference in 1L vs 2L efficacy in the P2. It was numerically lower but very small numbers. The bigger variable is the larger PDL (-) population in the P3
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up